Idera to Present at the 2017 Wedbush PacGrow Healthcare Conference
August 11 2017 - 11:00AM
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage
biopharmaceutical company developing toll-like receptor and RNA
therapeutics for patients with cancer and rare diseases, today
announced that the company will provide a corporate overview and
participate in a fireside chat, led by Joanna Horobin, M.B. Ch.B.,
Idera’s Chief Medical Officer at the 2017 Wedbush PacGrow
Healthcare Conference on Tuesday, August 15, 2017 at 9:45 a.m.
Eastern Time at the Le Parker Meridien Hotel in New York City.
Live audio webcast of Idera’s presentations will be accessible
in the Investors and Media section of Idera’s website at
http://www.iderapharma.com. Archived versions will also be
available on the Company’s website after the event for 90
days.
About Idera Pharmaceuticals Idera
Pharmaceuticals is a clinical-stage biopharmaceutical company
developing novel nucleic acid-based therapies for the treatment of
certain cancers and rare diseases. Idera’s proprietary technology
involves using a TLR-targeting technology, to design synthetic
oligonucleotide-based drug candidates to act by modulating the
activity of specific TLRs. In addition to its TLR programs, Idera
has created a third generation antisense technology platform using
its proprietary technology to inhibit the production of
disease-associated proteins by targeting RNA. To learn more about
Idera, visit www.iderapharma.com.
Investor and Media Contact
Robert Doody
VP, IR & Corporate Communications
617-679-5515 (office)
484‐639‐7235 (mobile)
rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024